All In Biotech

Drug Trial Radar · NCT06784193

Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

A Phase 1 First-in-Human, Open-Label, Multicenter Study of OP-3136 in Adult Participants With Advanced or Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 180 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

180

Planned (sponsor's estimate)

Start

Dec 16, 2024

Primary completion

May 30, 2027

Study completion Aug 30, 2027

Sponsor

Lead sponsor
Olema Oncology, Inc.Industry
Sponsor type
Industry
First posted
Jan 20, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a first-in-human, open-label, multicenter phase 1 study to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of OP-3136, a lysine acetyltransferases 6A and 6B (KAT6A/B) inhibitor, as monotherapy and in combination with other anticancer agents in participants with advanced solid tumors. This study consists of 2 parts: a dose escalation part (Part 1) and dose expansion part (Part 2).

Conditions

  • Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)
  • Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
  • Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC)
  • Metastatic Breast Cancer
  • Fulvestrant
  • Palazestrant

Interventions

  • OP-3136Drug

    Selective inhibitor of HAT enzymes KAT6A and KAT6B

  • FulvestrantDrug

    Selective estrogen receptor degrader (SERD)

  • PalazestrantDrug

    Complete estrogen receptor antagonist (CERAN)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with dose-limiting toxicities in the Dose Escalation ArmsTime frame: Up to 28 days
  2. Incidence of adverse events and laboratory abnormalitiesTime frame: Up to 26 months

Locations

25 sites in 6 countries. Site status is shown where the registry gives one.

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona · Recruiting

  • University of Colorado

    Aurora, Colorado · Recruiting

  • Florida Cancer Specialists

    Sarasota, Florida · Recruiting

  • University Medical Center - New Orleans

    New Orleans, Louisiana · Terminated

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • START - Midwest

    Grand Rapids, Michigan · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • The Ohio State University

    Columbus, Ohio · Recruiting

  • SCRI Oncology Partners

    Nashville, Tennessee · Recruiting

  • Tennessee Oncology

    Nashville, Tennessee · Recruiting

  • START - San Antonio

    San Antonio, Texas · Recruiting

  • START - Mountain Region

    West Valley City, Utah · Recruiting

  • The Kinghorn Cancer Centre

    Darlinghurst, New South Wales, Australia · Recruiting

  • Liverpool Hospital

    Liverpool, New South Wales, Australia · Recruiting

  • Macquarie University Clinical Trials Unit

    Macquarie, New South Wales, Australia · Recruiting

  • Cancer Research South Australia

    Adelaide, South Australia, Australia · Recruiting

  • Institut De Cancerologie De L'ouest

    Saint-Herblain, Loire-Atlantique, France · Recruiting

  • Hôpital Paris Saint-Joseph

    Paris, Paris, France · Recruiting

  • Institut Gustave Roussy

    Villejuif, Val-de-Marne, France · Recruiting

  • Queen Mary Hospital

    Hong Kong, Hong Kong, Hong Kong · Recruiting

  • START Dublin

    Dublin, Dublin, Ireland · Recruiting

  • START - Barcelona

    Barcelona, Barcelona, Spain · Recruiting

  • Start - Fjd

    Madrid, Madrid, Spain · Recruiting

  • START Madrid - CIOCC

    Madrid, Madrid, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.